UroGen Pharma (NASDAQ:URGN) Given Buy Rating at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of UroGen Pharma (NASDAQ:URGN - Free Report) in a report issued on Friday,Benzinga reports. D. Boral Capital currently has a $25.00 price target on the stock.

Other research analysts also recently issued reports about the stock. Oppenheimer reissued an "outperform" rating and set a $40.00 target price on shares of UroGen Pharma in a research report on Wednesday, October 16th. Guggenheim began coverage on UroGen Pharma in a report on Thursday, August 22nd. They set a "buy" rating and a $40.00 price objective for the company. EF Hutton Acquisition Co. I upgraded UroGen Pharma to a "strong-buy" rating in a research note on Monday, October 14th. Finally, HC Wainwright reiterated a "buy" rating and set a $60.00 price target on shares of UroGen Pharma in a research note on Tuesday, October 15th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, UroGen Pharma presently has a consensus rating of "Buy" and an average target price of $43.70.

UroGen Pharma Stock Performance

URGN stock traded up $0.08 during midday trading on Friday, hitting $12.29. The company's stock had a trading volume of 309,244 shares, compared to its average volume of 393,930. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77. The stock's 50-day moving average price is $12.28 and its 200 day moving average price is $13.96. UroGen Pharma has a 1 year low of $10.60 and a 1 year high of $20.70.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.55) earnings per share for the quarter, topping analysts' consensus estimates of ($0.84) by $0.29. The company had revenue of $25.20 million during the quarter, compared to analysts' expectations of $24.22 million. During the same period last year, the firm posted ($0.68) earnings per share. As a group, research analysts predict that UroGen Pharma will post -3.1 earnings per share for the current year.

Institutional Investors Weigh In On UroGen Pharma

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. grew its position in shares of UroGen Pharma by 90.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 8,100 shares of the company's stock valued at $103,000 after purchasing an additional 3,856 shares in the last quarter. BNP Paribas Financial Markets grew its holdings in UroGen Pharma by 221.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company's stock valued at $109,000 after buying an additional 5,890 shares in the last quarter. Intech Investment Management LLC bought a new stake in shares of UroGen Pharma during the third quarter valued at about $155,000. Verition Fund Management LLC purchased a new stake in shares of UroGen Pharma in the third quarter worth about $168,000. Finally, SG Americas Securities LLC bought a new position in shares of UroGen Pharma in the third quarter valued at approximately $179,000. Institutional investors own 91.29% of the company's stock.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.